Cincinnati Startup Raises $50 Million to Advance Hypertension Treatment Licensed from Roche

Cincinnati-based CinCor Pharma snagged $50 million in Series A financing, as well as rights to a Roche therapy for treatment-resistant hypertension and primary aldosteronism, a hormonal disorder that can lead to high blood pressure.

Click here to read the complete article.

Story excerpt provided by BioSpace.

Written by Alex Keown.

Originally published May 15, 2019.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: